Young child with Doctor

Latest press releases

Wednesday, 2 September 2015
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections AstraZeneca today announced positive topline results from RECAPTURE 1  and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI (ceftazidime-avibactam), as a treatment for adult hospitalised patients with complicated Urinary Tract Infections (cUTI), including pyelonephritis.
Wednesday, 2 September 2015
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an exclusive license to develop and commercialise FluMist® Quadrivalent in Japan.
Tuesday, 1 September 2015
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab AstraZeneca continues to sharpen focus on main therapy areas as collaboration with expert in dermatology is expected to accelerate the development of brodalumab for patients with psoriasis where there is high unmet need US and EU regulatory submission planned in moderate-to-severe psoriasis in Q4 2015
Monday, 31 August 2015
PEGASUS-TIMI 54 sub-analysis shows importance of continuing treatment with BRILINTA beyond one year following a heart attack Data presented at ESC Congress 2015 reinforce the need for long-term secondary prevention of cardiovascular events
Saturday, 29 August 2015
AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015 Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.
Monday, 24 August 2015
AstraZeneca appoints Dr Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
Monday, 24 August 2015
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumours.
Monday, 10 August 2015
Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
Thursday, 6 August 2015
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will explore the assets across a range of cancers, including in combination with its existing portfolio of immunotherapies.
Wednesday, 5 August 2015
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer. The Phase I/II study will evaluate the safety and efficacy of MedImmune’s investigational anti-PDL1 immune checkpoint inhibitor, durvalumab (MEDI4736), in combination with mocetinostat, Mirati’s investigational spectrum-selective histone deacetylase (HDAC) inhibitor.